U.S. Approves First Drug for ALS over 20 years

　　On May 5, 2017, the U.S. Food and Drug Administration granted approval to Radicava (edaravone), a drug used for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the first drug approved in the United States for the treatment of ALS over 20 years. It was developed by Mitsubishi Tanabe Pharma Corporation in Japan.
　　
　　ALS is known around the world as "Amyotrophic Lateral Sclerosis", which is a rare progressively neurodegenerative disorder. Motor nerve cells in the brain, brainstem and spinal are attacked, and muscles gradually atrophy then become weakened and paralyzed.
　　
　　At the same time, accompanied by symptoms such as speaking, swallowing and respiratory function decline, gradual atrophy and paralysis, the patient’s body is likely to be gradually frozen, so the disease is called "gradually frozen people".